

BP8: A Health and Energy Technology Company

INVESTOR DECK

BPH GLOBAL LIMITED
(ASX:BP8) www.bp8global.com



Offer Information and Disclaimer

This investor presentation (the “presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of BPH Global Limited (**BP8**). The presentation has been prepared to assist parties in making their own evaluation and for no other purpose. Parties should further carry out their own due diligence. It is not intended to form the basis of any investment decision or any other decisions.

No Representation or Warranty

No representation or warranty, express or implied, is or will be given by BP8 or any of its respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. This presentation does not purport to contain all of the information that may be required to evaluate a possible investment opportunity with respect to BP8, and does not constitute investment, tax or legal advice.

The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. BP8 disclaims any duty to update the information contained in this presentation. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM® or ® symbols, but parties assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

No Offer or Solicitation

This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities. No offer, sale or solicitation of any securities shall be made in any jurisdiction in which such offer, sale or solicitation would be prohibited. BP8 does not provide investors with personal advice that any investment made will be suitable for the investor’s personal circumstances or investment objectives. No representation or warranty is given by BP8 that any investment with respect to BP8 is suitable for the investor or that it will meet the investor’s investment objectives.

Eligible Recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation, you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Forward Looking Statements

This presentation contains “forward-looking statements”. These statements are based on management’s current expectations and beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and all of which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements. BP8 may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and the forward-looking statements should not be unduly relied upon. We do not undertake any obligation to update forward-looking statements following the date this presentation is made.

Any industry, market or other, similar data have been compiled from sources thought to be reliable, but have not been verified, and no assurance can be made as to their accuracy.

Risks

Please refer to Appendix 1 for Key Risks

Investment Highlights

BP8 is a diversified biotechnology company focused on the health and energy industries.



New management driving business development with focus on revenue growth

Primary focus on seaweed:

Cultivation and acquisition of **raw seaweed** for sale to **SE Asian markets**

Production of **bio-stimulant products** for sale to **Indian agricultural markets**


R&D - extraction of **nutraceuticals, minerals and hydrogen** to facilitate the commercialisation of **seaweeds** :

- sale of seaweed-based nutraceuticals and pharmaceutical ingredients to the food, nutrition, healthcare, health supplements, cosmetics and personal care industries
- sale of extracted seaweed-based rare earth minerals and nano minerals to the battery & minerals industries
- sale of seaweed-derived hydrogen to the energy supply industry

Market focus: India, Southeast Asia and China

Business Model: Seaweed

Sale of **Raw Seaweed** & Production & Sale of **Bio-stimulant**



Indonesian Seaweed Project

Announcement of establishment of Indonesian-based, seaweed focused joint venture business

JV to be owned & operated by a new wholly owned subsidiary of BP8

Joint venture partners already contributing assets to the JV

Initial focus on revenue generation from sales of raw seaweed

Development of seaweed-based bio-stimulant products for sale to India

Indicative of initial steps in the Company's pivot towards the Indian market

Business Development driver - Commercialisation potential

Enormous Potential

Indonesian territorial waters:




Sixth-largest exclusive economic zone in the world with **6,159,032 km²**.



81407 km coastline



The Siboga Expedition identified **555 species**. 56 species used for food and medicine



The global commodity-based seaweed industry; **36 million tons worth 18-28 billion dollars** (FAO, 2021, markets 2024)

6-8%

Growth per year

97%

cultivated (about 1 million tons wild harvest)


10.8%

CAGR (2022-2028)

Green (about 1200 species)

Brown (about 1750 species)

Red (about 6000 species)



Seaweed Business

Sourcing:

- Co-operative farming with coastal communities
- Land based farms using race pools near the sea
- Collectors and Village Co-operatives
- Corporate Farming





US\$23
billion

Food and food
ingredients used
in products

US\$2
billion

Hydrocolloids

US\$3
billion

Others
(biostimulant
/plastics etc;)

Total value **US\$20-30 billion**
(market insight 2024)

Other Markets for Seaweed

Pharmaceuticals

Nutraceuticals

Biostimulants



Alternative
Proteins



Farm Plot Metrics

Our Plot Metrics

- Length of one plot = 100 m
- Total no of 10 metre tubes = 100
- Size of one plot = 1000 sq. metres
- Anchoring involved in one plot = 150 kgs x 16
- Labour involved in establishing a plot = 8 ladies + 10 gents
- 2 days work



Farming *kappaphycus* will reduce the pressure on wild farming of other species.



- CO₂ up take through seawater plus de-acidification oceans (coral reef protection, biodiversity, food)
- P&N recycling, (run off from land or other aquaculture activities)
- High in Potassium and other important minerals
- Excellent source for fertiliser, animal feed and valued added materials and bioactives
- Circular economy and nutrient recycling
- Social impact coastal rural areas

Biodiversity



CARBON CAPTURE



COMMUNITY DEVELOPMENT



PRINCIPAL R&D GOALS

Extraction of seaweed-based nutraceuticals and pharmaceutical ingredients to infuse into food, nutrition, healthcare, health supplements, cosmetics and personal care products

Extraction of seaweed-based critical minerals for the sale into the battery & minerals industries


Sale of seaweed-derived bio-hydrogen to the energy supply industry

R&D Program Highlights

R&D activity that is focused on value-added products that attract higher sales margins


Business Model: Seaweed

Extraction of Nutraceuticals for use in the Food Industry




Business Model: Seaweed

Extraction of Minerals for use in the **battery** industry




Business Model: Seaweed

Extraction of Bio-hydrogen for use in the **energy** industry




Business Model: Seaweed

Recognition, qualification and issue of Blue Carbon Credits



Business Model: Bird's Nest



Capital Structure

ASX Code	Security	Number
BP8	ORDINARY SHARES	396,641,479
BP8O	LISTED OPTIONS EXP 07/07/2027 at \$0.05	44,166,876
BP8AA	OPTIONS EXP 5/12/2028 at \$0.05	1,020,000
BP8AA	OPTIONS EXP 16/12/2024 at \$0.05	100,000
BP8AA	OPTIONS EXP 18/12/2025 at \$0.05	1,000,000
BP8AA	OPTIONS EXP 11/12/2026 at \$0.02	115,877,226
BP8AI	OPTIONS EXP 09/04/2026 at \$0.085	5,000,000
BP8AJ	OPTIONS EXP 01/11/2027 at \$0.25	5,000,000
BP8AN	OPTIONS EXP 28/02/2027 at \$0.10	1,000,000
BP8AM	OPTIONS EXP 28/02/2027 at \$0.085	1,000,000
BP8AP	OPTIONS EXP 28/02/2025 at \$0.125	3,000,000
BP8AQ	OPTIONS EXP 28/02/2025 at \$0.25	1,500,000
BP8AR	OPTIONS EXP 28/02/2025 at \$0.375	500,000
BP8AO	OPTIONS EXP 28/02/2027 at \$0.05	100,000
BP8AU	OPTIONS EXP 01/09/2025 at \$0.09	5,533,338
BP8AA	OPTIONS EXP 11 Dec 2026 @\$0.02	5,816,828

Directors

Paul Stephenson

Non-executive Chair

Mr Paul Stephenson was a partner in the Sydney Office of HWL Ebsworth Lawyers (HWLE) for thirteen years before retiring from the partnership in 2017. Mr Stephenson remains a consultant with HWLE and is also a foreign (Australian) lawyer consultant with Israeli law firm Afik & Co. Mr Stephenson specialises in public and private equity fundraising, initial public offerings, backdoor listings and reverse mergers (both in Australia and the United States), and mergers and acquisitions involving both private and listed companies. Mr Stephenson has experience in a large number of industry sectors including resources, oil and gas, retailing, financial markets, and cannabis. Mr Stephenson has acted on many cross-border transactions and has expertise in equity capital markets and M&A transactions involving the USA, UK, China, Indonesia, Singapore, Malaysia, Hong Kong and Israel.

Francesco Cannavo

Executive Director

Mr Cannavo is an experienced public company director with significant business and investment experience working with companies operating across various industry sectors. Mr Cannavo is the founder of Golden Venture Capital, a corporate advisory firm based out of Melbourne, Australia. He has been instrumental in assisting many listed and unlisted companies achieve their growth potential by providing strategic advice on raising investment capital and completing strategic acquisitions. He is an entrepreneur with a strong network of investors and industry contacts in the public company sector in Australia and throughout the Asia-Pacific region. He has extensive experience in capital raisings, investment activities and IPOs.

Yanhua Huang

Non-executive Director

Mr Huang is a seasoned businessman and management consultant with almost 20 years of experience, accumulated from working in management consulting firm Accenture and audit firm KPMG, and also from managing companies in the construction, manufacturing and trading industries. Mr Huang graduated from the Lancaster University with a Bachelor degree and from the London School of Economics with a Master's degree.

Deepak Jha

Managing Director - Indonesia

With over 20 years of experience across Indonesia's trading, mining, manufacturing, and investment sectors, I specialize in driving growth in challenging and emerging markets. As a board member and shareholder at Mitra Agro Global and other ventures, I've successfully led large-scale projects with a focus on sustainable, profitable growth. My leadership approach emphasizes building resilient teams and strategic partnerships to maximize long-term value.

An advocate for the Blue Economy, I actively promote sustainable seaweed farming and ULVA cultivation in collaboration with UN GQSP Program among Indonesia's coastal communities, aligning investor returns with environmental impact.

Matthew Leonard

Managing Director/CEO

Mr Leonard is an accomplished and internationally proven business development professional. With over 12 years of outstanding record of achievement in demanding, complex and highly competitive markets. He possesses expertise across advertising, marketing and media event management sector, with recent focus on linking opportunities with high-net-worth individuals throughout Asia. Mr Leonard is also a member of Golden Venture Capital which provides corporate advisory and consultancy services. In this role, Mr Leonard has assisted a number of companies to raise capital throughout Asia and Australia.



BPH GLOBAL LIMITED

(ASX:BP8) [www. bp8global.com](http://www.bp8global.com)

- **Chairman:** Paul Stephenson
- **Email:** paul.stephenson1@icloud.com
- **CEO:** Matthew Leonard
- **Email:** matthew@goldenventurecapital.com

Authorised by the Board of Directors



Reinvigorated management driving a commercially sensible business plan with a pivot towards India



Deep expertise in sourcing and cultivating seaweed and the extraction of rare earth minerals, nano minerals and nutraceuticals from seaweed



Business focus on sales into high value markets



New Business Opportunities sought and welcomed to grow the Company's operations and revenue

Appendix 1: Key Risks

There are specific risks which relate directly to the Company's activities. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors.

The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Company's securities. The following is a summary of the more material matters to be considered and should be read in conjunction with specific matters referred to in the Company's announcements and reports. However, the summary is not exhaustive and potential investors should consult their professional advisors before deciding whether to apply for securities in the Company.

Business development and commercialisation

in the food, nutrition, healthcare, health supplements, cosmetics and personal care industry. The Company is focused on producing foods and products which deliver Traditional Chinese Medicine (TCM)-based health outcomes and the development of technologies to enable the extraction of hydrogen and minerals from seaweed for use in the energy and battery industries. Regarding TCM products, the Company focuses on the research & development (R&D), production and commercialisation of bird's nest and plant-based products, including seaweed and sea plants and hemp, to produce sustainable bird's nest and plant-based protein foods and nutraceutical and pharmaceutical ingredients (including CBD extracted from Hemp) for utilisation studies. Regarding the energy and battery industries, the Company focuses its R&D on the extraction of hydrogen and minerals from seaweed, leveraging its technologies developed for the extraction of nutraceuticals from seaweed. There can be no guarantee that the resulting products or extracted hydrogen and minerals will be commercialised, will be competitive in their respective markets, or will perform satisfactorily to their intended application.

Funding

Any inability of the Company to obtain additional funding as required, including under the proposed capital raising, would have a material adverse effect on the Company's business, its financial condition and performance and its ability to continue as a going concern. Accordingly, there is a material uncertainty that may cast doubt on the Company's ability to continue as a going concern. Should the Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the Company's financial statements.

Research and development risk

In order to remain competitive, the Company intends to continue to undertake research and development. The Company makes no representation that any of its research into or development of its technologies and products will be successful or that its technologies will be developed into products that are commercially exploitable.

Intellectual Property Risks

The Company will give consideration to whether it will pursue patent protection in Singapore and other jurisdictions in relation to technologies it develops. However, there is no guarantee that any future patent applications filed by the Company will not infringe competitor patents or that any such patent applications will be granted by authorities in key jurisdictions, given that patents on similar subject matter may have been granted.

Regulatory

Changes in relevant taxes, legal and administration regimes, accounting practice and government policies may adversely affect the financial performance of the Company.

Reliance on key management

The responsibility of overseeing the day-to-day operations and the strategic management of the Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the Company if one or more of these employees cease their employment.

Supply of Raw Materials

The Company may depend on the supply of raw materials to carry on elements of its business. Such supply may be disrupted because of weather, transportation and other matters outside the Company's control.

Product liability

The Company provides products for use in TCM and food products to deliver TCM-based health benefits, which are used and/or consumed by humans for therapeutic and other purposes. If the Company's product(s) causes damage or loss of life, claims may be made against the Company that it has supplied defective products.

Armed conflicts

The market price of the Company's Shares and Options may be adversely affected in the short to medium term by the economic uncertainty caused by the Ukraine conflict and the conflict in the Middle East.

Sovereign Risk

The Group's operations will continue to include a focus on markets in China and South East Asia, including but not limited to Singapore and Malaysia. Possible sovereign risks associated with operating in China and these South East Asian nations include, without limitation, changes in the terms of legislation, changes to taxation rates and concessions and changes in the ability to enforce legal rights. Any of these factors may, in the future, adversely affect the financial performance of the Company and the market price of the Company's Shares and listed Options.